Pfizer's Xeljanz jumps into ulcerative colitis fray with best-case FDA approval

[cafead]

via Xeljanz is on a roll. The Pfizer immunology blockbuster scored a big new approval in psoriatic arthritis last year, and now it has won an FDA green light to treat ulcerative colitis—a big new market that could significantly pad its sales.

article source